127 related articles for article (PubMed ID: 38350065)
21. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
22. [
Lawal IO; Popoola GO; Mahapane J; Kaufmann J; Davis C; Ndlovu H; Maserumule LC; Mokoala KMG; Bouterfa H; Wester HJ; Zeevaart JR; Sathekge MM
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287237
[TBL] [Abstract][Full Text] [Related]
23. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X; Heber D; Leike T; Beitzke D; Lu X; Zhang X; Wei Y; Mitterhauser M; Wadsak W; Kropf S; Wester HJ; Loewe C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):558-566. PubMed ID: 28932900
[TBL] [Abstract][Full Text] [Related]
24. CXCR4-directed [
Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
[TBL] [Abstract][Full Text] [Related]
25. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
[TBL] [Abstract][Full Text] [Related]
26.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
27. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
28. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
29. Chemokine receptor-4 targeted PET/CT with
Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
32. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
33. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of PET quantification in [
Rausch I; Beitzke D; Li X; Pfaff S; Rasul S; Haug AR; Mayerhoefer ME; Hacker M; Beyer T; Cal-González J
J Nucl Cardiol; 2022 Apr; 29(2):492-502. PubMed ID: 32696137
[TBL] [Abstract][Full Text] [Related]
35. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer
Hyafil F; Pelisek J; Laitinen I; Schottelius M; Mohring M; Döring Y; van der Vorst EP; Kallmayer M; Steiger K; Poschenrieder A; Notni J; Fischer J; Baumgartner C; Rischpler C; Nekolla SG; Weber C; Eckstein HH; Wester HJ; Schwaiger M
J Nucl Med; 2017 Mar; 58(3):499-506. PubMed ID: 27789718
[No Abstract] [Full Text] [Related]
36. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using
Weiberg D; Thackeray JT; Daum G; Sohns JM; Kropf S; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2018 Feb; 59(2):266-272. PubMed ID: 28775206
[TBL] [Abstract][Full Text] [Related]
37. Clinical Value of
Ding J; Li X; Liu S; Gao Y; Zheng G; Hacker M; Zhang Y; Tong A; Huo L
J Nucl Med; 2024 Jan; 65(1):117-124. PubMed ID: 38050127
[TBL] [Abstract][Full Text] [Related]
38. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
39. Advances in PET Imaging of the CXCR4 Receptor: [
Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
[TBL] [Abstract][Full Text] [Related]
40. Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]